Research programme: human papillomavirus vaccines - MediGene AG/Johns Hopkins University/Pennsylvania State University

Drug Profile

Research programme: human papillomavirus vaccines - MediGene AG/Johns Hopkins University/Pennsylvania State University

Alternative Names: AAVLP technology - MediGene; AAVLP vaccine carrying HPV L2 epitopes - MediGene AG

Latest Information Update: 27 Nov 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator MediGene AG
  • Developer Johns Hopkins University; MediGene AG; The Pennsylvania State University
  • Class Cancer vaccines; Synthetic vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer; Human papillomavirus infections

Most Recent Events

  • 08 Nov 2013 Preclinical development is ongoing in USA
  • 10 Apr 2012 Immunogenicity data from a preclinical trial in Human papillomavirus infections released by MediGene AG
  • 31 May 2011 MediGene and Johns Hopkins University agree to co-develop human papillomavirus vaccines (HPV) for the prevention of HPV-associated cancers in the US
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top